Group 1 - The article highlights the top three companies with the highest AH premium rates as Northeast Electric (00042) at 743.75%, Hongye Futures (03678) at 241.98%, and Andeli Juice (02218) at 236.37% [1] - The bottom three companies with the lowest AH premium rates include Ningde Times (03750) at -16.43%, Heng Rui Medicine (01276) at 1.82%, and Midea Group (00300) at 4.90% [1] - The article provides a detailed table of the top ten and bottom ten AH stocks based on premium rates and deviation values, indicating significant disparities in market valuations between H-shares and A-shares [1][2] Group 2 - The deviation values for the top three companies are Andeli Juice (02218) at 32.29%, Jinli Permanent Magnet (06680) at 22.19%, and Beijing Machinery (00187) at 20.80% [1] - The companies with the lowest deviation values include BYD Company (01211) at -98.36%, Northeast Electric (00042) at -64.84%, and Longpan Technology (02465) at -51.92% [1][2] - The article emphasizes that the deviation value represents the difference between the current premium rate and the average premium rate over the past 30 days, providing insights into market trends [2]

25 August 2025 | 1:44AM HKT Hengrui Medicine (600276.SS): Call takeaway: Guide sustainable collaboration income; Domestic innovative drug sales targets CAGR Guide sustainable licensing income; overseas development going smoothly: Management noted that BD revenue will become sustainable income for Hengrui, with more deals to expect from its substantial pipeline consisting of 100+ clinical-stage assets and 20+ new projects moving into clinical stage every year. The assets licensed-out to global partner have s ...

泡泡玛特将被纳入恒生中国企业指数成份股，成份股数目维持50只。 1.恒生指数 中国电信(00728)、京东物流(02618)、泡泡玛特(09992)将被纳入恒生指数成份股，成份股数目将由85只 增加至88只。 | | | | 代름 | 公司 | 恒指分类指数 | | --- | --- | --- | | 728 | 中国电信股份有限公司 - H 股 | 恒生工商业分类指数 | | 2618 | 京东物流股份有限公司 | 恒生工商业分类指数 | | 9992 | 泡泡玛特国际集团有限公司 | 恒生工商业分类指数 | 2.恒生中国企业指数 4.恒生综合指数 中国食品(00506)、恒瑞医药（600276）(01276)等将被纳入恒生综合指数成份股，冠城钟表珠宝 (00256)、思派健康(00314)等将被剔除。成份股数目由502只增加至504只。 恒瑞医药 中国电信 恒瑞医药 中国电信 泡泡玛特 京东物流 分时图 日K线 周K线 月K线 64.98 0.99 1.55% 1.66% 1.11% 0.55% 0.00% 0.55% 1.11% 1.66% 62.93 63.28 63.64 63.99 64.34 ...

江蘇恒瑞醫藥股份有限公司 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Jiangsu Hengrui Pharmaceuticals Co., Ltd. 孫飄揚先生 中國上海 2025年8月22日 於本公告日期，董事會成員包括(i)執行董事孫飄揚先生、戴洪斌先生、馮佶女 士、張連山先生、江寧軍先生及孫杰平先生；(ii)非執行董事郭叢照女士；及(iii) 獨立非執行董事董家鴻先生、曾慶生先生、孫金雲先生及周紀恩先生。 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1276） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 根據中華人民共和國的有關法例規定，江蘇恒瑞醫藥股份有限公司（「本公司」）在 上海證券交易所網站( www.sse.com.cn )刊發了以下公告。茲載列如下，僅供參閱。 承董事會命 江蘇恒瑞醫藥股份有限公司 董事長 二、说明会召开的时间、地点 会议召开时间：2025 年 9 月 1 日下 ...

Group 1 - The top three companies with the highest short positions as of August 15 are WuXi AppTec (02359), CATL (03750), and COSCO Shipping Holdings (01919), with short ratios of 14.92%, 14.41%, and 13.40% respectively [1][2] - The companies with the largest absolute increase in short positions are Heng Rui Medicine (01276), Yao Cai Securities (01428), and Modern Animal Husbandry (01117), with increases of 2.49%, 1.34%, and 1.31% respectively [1][2] - The companies with the largest absolute decrease in short positions are Ganfeng Lithium (01772), WuXi AppTec (02359), and Fourth Paradigm (06682), with decreases of -2.98%, -2.67%, and -2.28% respectively [1][2] Group 2 - The top ten companies with the highest short ratios include Ping An Insurance (02318) at 12.46%, Green Leaf Pharmaceutical (02186) at 12.36%, and Vanke Enterprises (02202) at 12.13% [2] - The companies with the most significant increases in short ratios include Heng Rui Medicine (01276) from 0.51% to 2.99%, Yao Cai Securities (01428) from 3.47% to 4.81%, and Modern Animal Husbandry (01117) from 4.74% to 6.05% [2] - The companies with the most significant decreases in short ratios include Ganfeng Lithium (01772) from 13.32% to 10.34%, WuXi AppTec (02359) from 17.59% to 14.92%, and Fourth Paradigm (06682) from 2.74% to 0.46% [2][3]

Group 1 - The article highlights the top three companies with the highest AH premium rates as Northeast Electric (00042) at 757.14%, Andeli Juice (02218) at 241.27%, and Hongye Futures (03678) at 236.23% [1] - The bottom three companies with the lowest AH premium rates include Ningde Times (03750) at -17.71%, Hengrui Medicine (01276) at 0.88%, and Midea Group (00300) at 6.01% [1] - The article also lists the top three companies with the highest deviation values, which are Andeli Juice (02218) at 39.59%, Beijing Machinery (00187) at 28.23%, and Kaisen New Energy (01108) at 18.28% [1] Group 2 - The article provides a detailed table of the top ten AH stocks by premium rate, showing significant premiums for companies like Northeast Electric and Andeli Juice [1] - It also includes a table of the bottom ten AH stocks by premium rate, indicating negative premiums for companies like Ningde Times and Hengrui Medicine [2] - The deviation values for the top ten AH stocks are presented, with Andeli Juice leading, indicating a significant difference from their average premium rates over the past 30 days [2]

Investment Rating - The report assigns a neutral rating to the company with a target price of HKD 70.40, indicating a potential downside of 9.4% from the current closing price of HKD 77.75 [6][11]. Core Insights - The company has experienced significant growth in innovative drug sales, with a year-on-year revenue increase of 16% in 1H25, driven by a 23% increase in innovative drug sales, which now account for 55% of product sales revenue [6][12]. - The management plans to increase R&D investment while keeping the total R&D expenditure as a percentage of total revenue below 30% [6]. - The company has achieved several business development (BD) milestones, including the approval of six innovative drugs in 1H25 and expectations to launch 47 new products and indications from 2025 to 2027 [6][12]. Summary by Sections Financial Performance - In 1H25, the company reported a revenue of approximately RMB 20 billion from collaboration income, up from RMB 14 billion in 1H24 [6]. - The gross margin improved by 0.4 percentage points to 86.6%, with a notable decrease in selling, general, and administrative (SG&A) expenses and R&D expense ratios [6][12]. - The projected revenue for 2025 is RMB 32,543 million, with a net profit forecast of RMB 7,698 million [12]. Business Development - The company has successfully completed three overseas agreements in 2025, including a deal with GSK valued at approximately USD 12 billion [6]. - The management's targets for the employee stock ownership plan include achieving over 25% annual growth in innovative drug sales and submitting 5-8 new drug applications each year from 2025 to 2027 [6]. Valuation - The report raises the revenue forecast for 2025-2027 by about 2% and the net profit forecast by 7-8% to reflect the contributions from various BD transactions and expected improvements in profit margins [6][12]. - The DCF valuation model indicates a fair value of HKD 70.40 per share, with no premium or discount applied to the Hong Kong shares compared to A-shares [6][7].

8月20日，恒瑞医药（股票代码：600276.SH；01276.HK）发布2025年半年度报告。报告显示，2025年 上半年，公司实现营业收入157.61亿元，同比增长15.88%；归属于上市公司股东的净利润44.50亿元， 同比增长29.67%；经营性现金流净额达43.00亿元，同比增长41.80%。营收、净利及经营性现金流净额 均创往年同期新高，业绩进入爆发增长期。公司持续加大创新力度，维持较高的研发投入，报告期内公 司研发投入38.71亿元，其中费用化研发投入32.28亿元。 为了增强团队凝聚力及公司核心竞争力，充分发挥长效激励机制，恒瑞医药还同时公告将回购10-20亿 元的股份，用于实行新的员工持股计划，2025年激励规模不超过1400万股。 创新药销售引领业绩增长，对外许可成常态化业务 从业绩角度来看，持续的高强度研发投入加快公司转型升级步伐，公司迈入了创新药丰收期，创新药收 入持续提升。2025年上半年公司创新药销售及许可收入95.61亿元，占公司营业收入比重60.66%，其中 创新药销售收入75.70亿元。瑞维鲁胺、达尔西利、恒格列净等医保内创新药优异的临床数据在实践中 得到广泛验证，临床价值获 ...

21 August 2025 | 2:08AM HKT Hengrui Medicine (600276.SS): First take: 2Q product sales in-line; Earnings beat with lower R&D In-line 2Q product sales driven by innovative drugs: 2Q revenue was Rmb8.6bn (+12.5% y/y) with product sales of around Rmb7.1bn (+15% y/y, on par with GSe), accelerated from 11% y/y in 1Q25. Looking at 1H growth of 13% y/y product sales, it was on-par vs. Hansoh (+13.2% y/y) and beat Sino Biopharm's +11% y/y, driven by 20%+ growth in novel drugs. Generic sales saw slight growth in 1H, ...

中信证券研报认为，展望8月份，半年报业绩期将是港股行情是否延续的重要节点，结合政策方面"反内 卷"的广泛影响与快速落地，预计短期市场可能由前期的流动性驱动转往业绩驱动与政策验证的共振阶 段。随着市场焦点从"预期"转往"兑现"，业绩超预期、指引上修的个股有望继续受益;"反内卷"政策的边 际变化也将成为对应行业定价的核心变量。 兴业证券发布研报称，长期继续坚定看多做多港股。全球投资者特别是中国投资者对于中国股市的牛市 思维正在持续增强。兴业证券维持此轮港股行情将走出超级长牛的判断。中短期，维持下半年港股行情 震荡向上，持续创新高的判断。美联储降息可能只是时间问题，聚焦联储降息和美元走软对港股流动性 的进一步刺激动能。 本文转载自"腾讯自选股"，智通财经编辑：李佛。 恒生指数高开0.2%，恒生科技指数跌0.03%。创新药概念集体高开，恒瑞医药绩后涨超1%;稳定币股大 幅走强，众安在线涨超6%。 关于港股后市 华泰证券指出，当下，市场处于交易主线相对缺乏、海外及国内重要事件等待验证的关键阶段，也正是 仓位调整的窗口期，我们对后续行情并不悲观。 中报视角下，建议关注：1)高景气估值性价比的游 戏、互联网电商龙头;2)估 ...